Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Acadia Pharmaceuticals sell The Goldman Sachs Group, Inc.

Start price
€20.93
07.08.25 / 50%
Target price
€14.58
07.08.26
Performance (%)
20.07%
End price
€25.13
08.08.26
Summary
This prediction ended on 08.08.26 with a price of €25.13. The prediction closed with a disappointing performance of 20.07%. The_Goldman_Sachs_Gr has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Acadia Pharmaceuticals 2.316% 2.316% 21.379%
iShares Core DAX® -0.874% 5.325% 6.865%
iShares Nasdaq 100 -0.381% 1.979% 25.696%
iShares Nikkei 225® -1.676% 1.952% 41.443%
iShares S&P 500 -0.655% 2.069% 21.405%

Comments by The_Goldman_Sachs_Gr for this prediction

In the thread Acadia Pharmaceuticals diskutieren
Prediction Sell
Perf. (%) 20.07%
Target price 14.578
Change
Ends at 07.08.26

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat

In the thread Trading Acadia Pharmaceuticals
Prediction Sell
Perf. (%) 20.07%
Target price 14.578
Change
Ends at 07.08.26

Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten